로딩 중…
StockDiggingStockDigging

Fresenius Medical Care AG & Co. KGaA

FMS· NYSE
DEDE
$22.20+0.59%
2026-09-18

Financials

Valuation Metrics

Fresenius Medical Care AG & Co. KGaA's Market Cap is $11.92B. At end of 2025 it was $14.17B. Ranked #831 of 3,121 in US market (top 27%), #570 of 1,658 on NYSE (top 34%), #53 of 205 in Health Care Equipment & Services (top 26%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$11.92B
Revenue$21.95B
Net Income$1.06B
Total Assets$36.76B
Net Assets$14.75B
Employees108,165
Value
P/E11.25x
P/B0.81x
PEG0.26x
P/S0.54x
EV/EBITDA6.10x
FCF Yield16.77%
Profitability
ROE7.18%
ROA2.88%
Op. Margin9.74%
Revenue Growth-0.47%
Earnings Growth42.86%
Financial Health
Debt Ratio141.45%
Total Debt$12.88B
FCF$2.00B
Cash$1.25B
Current Ratio1.07x
Net Debt/EBITDA3.01x
Dividend
Div. Yield0.02%
Div. Growth16.23%
Performance
1Y Return-12.80%
1M Return-6.88%
From 52W High-19.68%
1Y MDD-26.34%
Trading
Volume727,822 shares
Trading Value$16M
Per Share
EPS$1.97
BPS$27.46

Company Info

CEO Helen Giza
Employees 108,165
HQ Bad Homburg, DE

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.